Drug intelligence / Profile preview

hyperforin

Development stage
Phase 2
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral
01

Overview

Hyperforin is a phloroglucinol derivative and the primary active constituent responsible for the antidepressant and anxiolytic properties of St. John's wort (Hypericum perforatum) extracts. It acts as a broad-spectrum reuptake inhibitor of monoamines, including serotonin, norepinephrine, dopamine, as well as GABA and glutamate. Unlike conventional antidepressants that target specific transporters, hyperforin inhibits neurotransmitter uptake by activating the transient receptor potential ion channel TRPC6, leading to increased intracellular sodium and calcium concentrations which in turn inhibit monoamine reuptake. Hyperforin also induces cytochrome P450 enzymes CYP3A4 and CYP2C9 via activation of the pregnane X receptor (PXR), contributing to significant drug interactions when St. John's wort is used concurrently with other medications. In addition to its antidepressant effects, hyperforin exhibits anxiolytic-like activity, cognition-enhancing effects in vivo, antioxidant properties in vitro, anticyclooxygenase-1 activity, and potential anticarcinogenic effects[1][2][5][6][8].

02

Targets

DRD1 (Dopamine D1 Receptor)DAT (Dopamine plasma membrane transport protein)SLC1A2 (Glutamate Transporter 1)SLC6A1 (Sodium- and chloride-dependent GABA transporter 1)NET (Norepinephrine Transporter)PXR (Pregnane X receptor)SERT (Sodium-dependent serotonin transporter)TRPC6 (Transient receptor potential canonical type 6)

Beyond the preview

Go deeper on hyperforin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyperforin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call